A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2018-02, Vol.180 (3), p.445-448
Hauptverfasser:	Kirschbaum, Mark H., Frankel, Paul, Synold, Timothy W., Zain, Jasmine, Claxton, David, Tuscano, Joseph, Newman, Edward M., Gandara, David R., Lara, Primo N.
Format:	Artikel
Sprache:	eng
Schlagworte:	California Cancer clinical trials Hematology Humans Myelodysplastic syndrome Myelodysplastic Syndromes - diagnosis Myelodysplastic Syndromes - drug therapy Myelodysplastic Syndromes - mortality Receptors, Vascular Endothelial Growth Factor - administration & dosage Receptors, Vascular Endothelial Growth Factor - therapeutic use Recombinant Fusion Proteins - administration & dosage Recombinant Fusion Proteins - adverse effects Recombinant Fusion Proteins - therapeutic use Treatment Outcome Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!